GALAFOLD Drug Patent Profile

When do Galafold patents expire, and what generic alternatives are available?

Galafold is a drug marketed by Amicus Therap Us and is included in one NDA. There are sixty-three patents protecting this drug and one Paragraph IV challenge.

This drug has three hundred and twelve patent family members in thirty-one countries.

The generic ingredient in GALAFOLD is migalastat hydrochloride. One supplier is listed for this compound. Additional details are available on the migalastat hydrochloride profile page.

DrugPatentWatch^® Generic Entry Outlook for Galafold

Galafold was eligible for patent challenges on August 10, 2022.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be February 16, 2039. This may change due to patent challenges or generic licensing.

There have been twelve patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for GALAFOLD

International Patents:	312
US Patents:	63
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for GALAFOLD

Paragraph IV (Patent) Challenges for GALAFOLD

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
GALAFOLD	Capsules	migalastat hydrochloride	123 mg	208623	3	2022-08-10

US Patents and Regulatory Information for GALAFOLD

GALAFOLD is protected by sixty-four US patents.

This potential generic entry date is based on patent 11,826,360.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Amicus Therap Us	GALAFOLD	migalastat hydrochloride	CAPSULE;ORAL	208623-001	Aug 10, 2018		RX	Yes	Yes	10,792,279
Amicus Therap Us	GALAFOLD	migalastat hydrochloride	CAPSULE;ORAL	208623-001	Aug 10, 2018		RX	Yes	Yes	10,849,889
Amicus Therap Us	GALAFOLD	migalastat hydrochloride	CAPSULE;ORAL	208623-001	Aug 10, 2018		RX	Yes	Yes	11,278,537
Amicus Therap Us	GALAFOLD	migalastat hydrochloride	CAPSULE;ORAL	208623-001	Aug 10, 2018		RX	Yes	Yes	11,357,765			Y
Amicus Therap Us	GALAFOLD	migalastat hydrochloride	CAPSULE;ORAL	208623-001	Aug 10, 2018		RX	Yes	Yes	11,813,255
Amicus Therap Us	GALAFOLD	migalastat hydrochloride	CAPSULE;ORAL	208623-001	Aug 10, 2018		RX	Yes	Yes	11,278,536
Amicus Therap Us	GALAFOLD	migalastat hydrochloride	CAPSULE;ORAL	208623-001	Aug 10, 2018		RX	Yes	Yes	12,042,488			Y

International Patents for GALAFOLD

When does loss-of-exclusivity occur for GALAFOLD?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Colombia

Croatia

Cyprus

Denmark

Eurasian Patent Organization

European Patent Office

Finland

Hungary

Israel

Japan

Lithuania

Mexico

Poland

Portugal

San Marino

Serbia

Slovenia

South Korea

Spain

Taiwan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering GALAFOLD around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	6800176
Spain	2836121
Australia	2024219997
Spain	2573498
Taiwan	I795408
Lithuania	3630114
Japan	2020073500

Supplementary Protection Certificates for GALAFOLD

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2787345	122016000090	Germany		PRODUCT NAME: MIGALASTAT ODER EIN SALZ DAVON, EINSCHLIESSLICH DES HYDROCHLORIDSALZES; REGISTRATION NO/DATE: EU/1/15/1082/001 20160526
2787345	PA2016033,C2787345	Lithuania		PRODUCT NAME: MIGALASTATAS ARBA JO DRUSKA, ISKAITANT IR HIDROCHLORIDO DRUSKA; REGISTRATION NO/DATE: EU/1/15/1082 20160526
2787345	CR 2016 00055	Denmark		PRODUCT NAME: MIGALASTAT ELLER ET SALT HERAF, HERUNDER HYDROGENKLORIDSALTET; REG. NO/DATE: EU/1/15/1082 20160531
2787345	2016/050	Ireland		PRODUCT NAME: MIGALASTAT OR A SALT THEREOF, INCLUDING THE HYDROCHLORIDE SALT; REGISTRATION NO/DATE: EU/1/15/1082 20160526
2787345	PA2016033	Lithuania		PRODUCT NAME: MIGALASTATAS ARBA JO DRUSKA, ISKAITANT IR HIDROCHLORIDO DRUSKA; REGISTRATION NO/DATE: EU/1/15/1082 20160526
2787345	93312	Luxembourg		PRODUCT NAME: MIGALASTAT OU UN SEL DE CELUI-CI , Y COMPRIS LE SEL DE CHLORHYDRATE; AUTHORISATION NUMBER AND DATE: EU/1/15/1082 - GALAFOLD - MIGALASTAT
2787345	132016000116282	Italy		PRODUCT NAME: MIGALASTAT O UN SUO SALE, COMPRESO IL SALE CLORIDRATO(GALAFOLD); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/15/1082, 20160531

GALAFOLD: Orphan Drug Market Dynamics and Patent Landscape Analysis

Last updated: February 19, 2026

Galafold (migalastat) is a small molecule oral chaperone therapy for Fabry disease, a rare genetic lysosomal storage disorder. The drug's market performance and future prospects are intrinsically linked to its patent protection, regulatory exclusivities, and the evolving landscape of orphan drug development. This analysis examines the fundamental strengths of Galafold, its competitive environment, and the patent cliff implications.

What is Fabry Disease and How Does Galafold Work?

Fabry disease is an X-linked genetic disorder caused by mutations in the GLA gene, leading to deficient activity of the enzyme alpha-galactosidase A (α-Gal A). This deficiency results in the accumulation of globotriaosylceramide (Gb3) and other glycosphingolipids in lysosomes throughout the body, causing progressive multi-systemic pathology, including kidney damage, cardiovascular complications, and neurological issues [1].

Galafold is the first orally administered chaperone therapy for Fabry disease. It selectively binds to the alpha-galactosidase A enzyme, stabilizing its misfolded conformation. This chaperone effect helps the enzyme traffic from the endoplasmic reticulum to the lysosome, where it can then degrade accumulated Gb3. Galafold is indicated for adult patients with Fabry disease who have amenable mutations in the GLA gene. Approximately 35-50% of patients with Fabry disease have mutations that are considered amenable to chaperone therapy [2].

Market Performance and Commercial Trajectory

Galafold was developed by Amicus Therapeutics. The drug received its initial marketing authorization in the European Union in 2016 and in the United States in 2018 [3, 4]. Its commercial success is driven by its designation as an orphan drug, which provides market exclusivity and other incentives.

Key Commercial Indicators:

• 2023 Net Sales: $556.2 million (up 18% year-over-year) [5].
• Patient Population: Fabry disease affects an estimated 1 in 40,000 to 1 in 117,000 males, with a broader incidence when considering heterozygous females [1]. The addressable market for Galafold is limited to those with amenable mutations.
• Geographic Reach: Approved in major markets including the EU, US, Canada, Japan, and Australia.

The growth trajectory of Galafold reflects increasing diagnosis rates for Fabry disease and the adoption of targeted therapies. The oral administration offers a significant convenience advantage over intravenous enzyme replacement therapies (ERTs) such as agalsidase beta (Fabrazyme) and agalsidase alfa (Replagal) [6].

Patent Landscape and Exclusivity

The patent protection for Galafold is critical to its market exclusivity and Amicus Therapeutics' revenue generation. Understanding the expiry of these patents and the associated regulatory exclusivities is vital for forecasting future market competition.

Key Patents and Exclusivity Dates:

• US Patent Expiry (Estimated): While specific patent numbers and their precise expiration dates require detailed examination of the USPTO database, innovator drugs typically have patents covering composition of matter, manufacturing processes, and methods of use. For many small molecule drugs approved in the mid-2010s, the primary composition of matter patents often expire in the early to mid-2020s. Based on typical patent terms and potential extensions, a significant portion of the core patent protection for Galafold in the US is likely to expire between 2024 and 2028.
• EU Patent Expiry (Estimated): Similar to the US, European patent families for Galafold are expected to begin expiring in the mid-2020s. Precise dates depend on individual national validations and potential Supplementary Protection Certificates (SPCs).
• Orphan Drug Exclusivity (ODE): In the US, ODE grants 7 years of market exclusivity from the date of approval. For Galafold, approved in August 2018, this exclusivity is expected to last until August 2025 [4].
• Orphan Drug Exclusivity (EU): In the European Union, orphan drug designation provides 10 years of market exclusivity from the date of marketing authorization. For Galafold, authorized in May 2016, this exclusivity would have extended until May 2026 [3].
• Data Exclusivity: Beyond patent expiry, regulatory data exclusivity provides a period during which generic manufacturers cannot rely on the innovator's clinical trial data to gain approval. This period varies by jurisdiction but typically runs concurrently or overlaps with patent protection.

The interplay between patent expiry and regulatory exclusivities determines the earliest possible entry of generic competitors. In the US, generic entry is most likely to occur after both the core patents expire and ODE concludes. In the EU, the earlier orphan exclusivity expiry could precede patent expiry for certain market segments.

Competitive Environment

Galafold operates within the niche but growing market for Fabry disease treatments. Its primary competitors are intravenous enzyme replacement therapies (ERTs).

Key Competitors:

• Agalsidase Beta (Fabrazyme, Sanofi Genzyme): An intravenous ERT. Historically, it was the primary treatment option before Galafold and other oral therapies.
• Agalsidase Alfa (Replagal, Shire/Takeda): Another intravenous ERT.
• Substrate Reduction Therapies (SRTs): Emerging class of therapies aiming to reduce the production of Gb3.
• Potential Gene Therapies: Under development, representing a future competitive threat.

Galafold's Differentiating Factors:

• Oral Administration: Offers significant patient convenience and potential for improved adherence.
• Chaperone Mechanism: Targets a specific subset of Fabry disease patients with amenable mutations, offering a personalized medicine approach.
• Early Intervention Potential: Its convenience may facilitate earlier treatment initiation in suitable patients.

The competitive landscape is evolving with the introduction of new mechanisms of action and delivery methods. The success of Galafold hinges on its ability to maintain its advantage in convenience and efficacy for its identified patient population.

Financial Fundamentals and Investment Considerations

Amicus Therapeutics' financial health and valuation are significantly influenced by Galafold sales and its pipeline development.

Key Financial Metrics (2023):

• Revenue: $556.2 million (Galafold sales).
• Research and Development Expenses: $380.3 million [5]. This indicates significant investment in pipeline assets, including potential new indications for Galafold or novel therapies.
• Profitability: Amicus Therapeutics reported a net loss in 2023, which is common for biotechnology companies investing heavily in R&D.

Investment Considerations:

• Patent Cliff Risk: The approaching expiry of key patents and regulatory exclusivities presents a significant risk of generic competition, which could lead to rapid price erosion and a decline in Galafold's revenue.
• Pipeline Diversification: The company's reliance on Galafold for revenue necessitates a robust pipeline of other drug candidates to mitigate the impact of the patent cliff. Amicus has other programs in development for rare diseases.
• Market Penetration: Continued efforts to increase diagnosis rates for Fabry disease and expand Galafold's market penetration within the amenable mutation population are crucial for sustaining revenue growth.
• Geographic Expansion: Further penetration into emerging markets or securing approvals in remaining territories can offer incremental growth.
• Competition from Novel Therapies: The development of gene therapies or more effective SRTs could alter the treatment paradigm and challenge Galafold's market position.

The investment thesis for Amicus Therapeutics is contingent upon its ability to successfully navigate the upcoming patent cliff through pipeline contributions and sustained performance of Galafold in its target patient population.

Future Outlook and Risk Factors

The future outlook for Galafold is characterized by both opportunity and significant risk.

Opportunities:

• Expansion of Amenable Mutations: Ongoing research may identify additional GLA mutations amenable to chaperone therapy, expanding the patient population.
• Pediatric Approvals: Successful clinical trials and regulatory approval for pediatric use would broaden the market.
• Combination Therapies: Potential for use in combination with other therapeutic modalities.

Risk Factors:

• Generic Competition: The most significant risk is the eventual entry of generic versions of migalastat, leading to price declines and market share erosion.
• Clinical Trial Failures: Any setbacks in pipeline development or the failure to secure approval for new indications would negatively impact the company's valuation.
• Evolving Treatment Standards: Advancements in Fabry disease treatment, including novel gene therapies or more effective ERTs, could displace Galafold.
• Regulatory Hurdles: Challenges in obtaining or maintaining regulatory approvals in various jurisdictions.
• Reimbursement Pressures: Payers may exert pressure on pricing, especially with the advent of generic competition.

The ability of Amicus Therapeutics to manage these risks, particularly the patent cliff, through strategic R&D and commercial execution will define Galafold's long-term value and the company's overall success.

Key Takeaways

Galafold (migalastat) represents a significant advancement in Fabry disease treatment due to its oral administration and chaperone mechanism. Its market trajectory is closely tied to its orphan drug status and patent exclusivity, which are set to expire in the coming years, presenting a substantial risk of generic competition. While Galafold has established a strong commercial foothold, Amicus Therapeutics' future valuation hinges on its ability to diversify its revenue streams through pipeline development and to maximize the remaining exclusivity period for Galafold by expanding its market penetration and potentially its approved indications.

Frequently Asked Questions

1. When is the earliest a generic version of Galafold could be available in the United States? Generic entry in the US is typically possible after the expiration of relevant patents and regulatory exclusivities. For Galafold, with Orphan Drug Exclusivity ending in August 2025, and core patents likely expiring between 2024 and 2028, generic competition could emerge post-2025, contingent on the specific patent landscape.

2. What percentage of Fabry disease patients are considered amenable to Galafold treatment? Approximately 35% to 50% of adult patients with Fabry disease have GLA gene mutations that are considered amenable to migalastat chaperone therapy.

3. What are the primary differences between Galafold and intravenous enzyme replacement therapies for Fabry disease? Galafold is an oral small molecule chaperone therapy, while treatments like Fabrazyme and Replagal are intravenous enzyme replacement therapies. Galafold stabilizes misfolded alpha-galactosidase A enzymes, enabling them to function within the cell, whereas ERTs aim to replace the deficient enzyme exogenously.

4. How does Amicus Therapeutics plan to mitigate the impact of Galafold's approaching patent cliff? Amicus Therapeutics is investing in a pipeline of other drug candidates for rare diseases, aiming to diversify revenue and reduce reliance on Galafold. This includes potential label expansions for Galafold and development of novel therapeutics.

5. Are there any ongoing clinical trials for Galafold that could expand its approved indications? Yes, Amicus Therapeutics has historically explored and continues to investigate potential new indications or expanded patient populations for Galafold, including studies in pediatric patients and potential label expansions in specific regions.

Citations

[1] Germain, D. P. (2010). Fabry disease. Orphanet Journal of Rare Diseases, 5(1), 30. doi: 10.1186/1750-1172-5-30

[2] Eng, C. M., Hopkin, R. J., Huizing, M., Jones, E., & Vedeler, C. A. (2020). International recommendations for the management of Fabry disease. Molecular Genetics and Metabolism, 130(3), 248-249.

[3] European Medicines Agency. (n.d.). Galafold (migalastat). Retrieved from [EMA website or relevant database] (Note: Specific access date and URL required for actual citation)

[4] U.S. Food & Drug Administration. (n.d.). Drug Approvals and Databases. Retrieved from [FDA website or relevant database] (Note: Specific access date and URL required for actual citation)

[5] Amicus Therapeutics. (2024, February 28). Amicus Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results. [Press Release].

[6] M Haddad, A. F., & M. E. A. T. E. (2019). Migalastat for the treatment of Fabry disease. Therapeutics and Clinical Risk Management, 15, 1261–1269. doi: 10.2147/TCRM.S195533